Is lack of response to single-agent chemotherapy in gestational trophoblastic disease associated with dose scheduling or chemotherapy resistance?

Gynecologic Oncology

Volumn 85, Issue 1, 2002, Pages 36-39

  Kohorn, Ernest I ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN; DACTINOMYCIN;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; DOSE RESPONSE; FEMALE; HUMAN; HYDATIDIFORM MOLE; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME; TROPHOBLASTIC DISEASE;

EID: 0036222987     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2001.6533     Document Type: Article

References (5)

1. A prospective randomized comparison of methotrexate, dactinomycin, and chlorambucil versus methotrexate, dactinomycin, cyclophosphamide, doxorubicin, melphalan, hydroxyurea, and vincristine in "poor prognosis" metastatic gestational trophoblastic disease: A Gynecologic Oncology Group study
2. Decision making for chemotherapy administration in patients with low risk gestational trophoblastic neoplasia
3. Actinomycin-D as a primary agent for gestational trophoblastic disease
4. Single-agent methotrexate chemotherapy for the treatment of nonmetastatic gestational trophoblastic tumors
5. Rapid escalation of weekly intramuscular methotrexate for nonmetastatic gestational trophoblastic disease; a Gynecologic Oncology Group study